Replies to post #17818 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

I (Bernstein's Ronny Ga) previously estimated generic competition could cause Copaxone sales to decline by 70% in year one - 51% decline in price and 40% loss of market share.According to Gal clients are making large up-front orders with Mylan at discounted prices. Fears exist that a patent dispute with Teva could result in an injunction forcing Mylan to halt sales for a period of time.

Wow, Let the fight begin. Not good for Glatopia in any dosage form.

Well, at least Momenta's goals were met, bonus's and options for everyone!!!!